SCHEMBL1359554

SCHEMBL1359554

CS(=O)(=O)NC[C@@H]1CCCNC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.40
APLNR P35414 2/20 0.39
CPN1 P15169 1/20 0.37
CPB2 Q96IY4 1/20 0.37
EPHX1 P07099 1/20 0.37
BRD4 O60885 1/20 0.36
ATAD2 Q6PL18 1/20 0.36
KMT2A Q03164 1/20 0.35
PBK Q96KB5 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
JAK2 O60674 3/20 0.34
ROCK2 O75116 3/20 0.34
ROCK1 Q13464 3/20 0.34
JAK3 P52333 2/20 0.34
IKBKB O14920 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
EED O75530 1/20 0.33
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359859 1.00 SCN9A (0.40) SCN9AAPLNRCPN1CPB2EPHX1
SCHEMBL1358284 1.00 SCN9A (0.40) SCN9AAPLNRCPN1CPB2EPHX1
SCHEMBL10059949 0.89 GABRA5 (0.41) SCN9ABRD4ATAD2JAK2JAK3
SCHEMBL1348800 0.89 GABRA5 (0.41) SCN9ABRD4ATAD2JAK2JAK3
SCHEMBL321293 0.89 GABRA5 (0.41) SCN9ABRD4ATAD2JAK2JAK3
SCHEMBL21192917 0.83 SCN9A (0.39) SCN9AAPLNRCPN1CPB2EPHX1
SCHEMBL21664287 0.81 APLNR (0.42) SCN9AAPLNRCPN1CPB2EPHX1
SCHEMBL21358565 0.81 JAK2 (0.32) JAK2JAK3JAK1TYK2KDM1A
Hydrochloric Acid SCHEMBL1702766 0.79 JAK2 (0.31) JAK2JAK3JAK1TYK2
SCHEMBL8391559 0.78 ADH1B (0.41) EPHX1KMT2AJAK2JAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS SCN9A 4081/4885APLNR 4517/4885CPN1 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.